### Version 8.0 – Significant Updates

<table>
<thead>
<tr>
<th>Page #</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>6</td>
<td>• Significant Updates: Case and Contact Management Responsibilities section</td>
</tr>
<tr>
<td>8</td>
<td>• New Section: Testing section including addition of Table 1: Testing Reference Documents and Table 2: Managing Indeterminate Results</td>
</tr>
<tr>
<td>12</td>
<td>• Significant Updates: Case and Contact Management section including new section on case and contact management indicators</td>
</tr>
<tr>
<td>13</td>
<td>• Significant Updates: Case Management section including addition of Table 3: Assessing Timing of Non-Test Based Clearance and Table 4: Management of Cases after Clearance with new Symptoms, Exposures and/or Positive Test Results</td>
</tr>
<tr>
<td>22</td>
<td>• Significant Updates: Contact Management section including addition of Table 5: Contact Follow-up when Case is Asymptomatic at Time of Positive Specimen Collection Date; and Table 8: Managing Symptomatic Contacts • Updates to Table 6: Contact Management Based on Exposure Setting and Type and Table 7: Contact Self-Isolation and Self-Monitoring by Risk Level</td>
</tr>
<tr>
<td>36</td>
<td>• Minor Updates: Travelers from Outside of Canada section</td>
</tr>
<tr>
<td>39</td>
<td>• Minor Updates: Additional Resources section</td>
</tr>
</tbody>
</table>

**General**

- Re-ordering of information for improved flow
- Updated formatting to align with other Ministry guidance
- Updated contact guidance to 2 exposure risk levels: high-risk and low-risk (removed medium-risk exposures)
- Appendices and other supporting documents are now found on the [Ministry website](https://www.moh.gov.on.ca) and are hyperlinked throughout this guidance

---

Ministry of Health. Health System Emergency Management Branch  
1075 Bay Street, Suite 810. Toronto, Ontario. Canada, M5S 2B1  
416-212-8022 (local); 1-866-212-2272 (long distance).  
[Emergencymanagement.moh@ontario.ca](mailto:Emergencymanagement.moh@ontario.ca)
# Table of Contents

List of Tables ........................................................................................................................................................................ 4

Management of Cases and Contacts of COVID-19 in Ontario ................................................................. 5

Case and Contact Management Responsibilities ..................................................................................... 6

Testing ....................................................................................................................................................................................... 8
  Management of individuals awaiting testing results ........................................................................ 9
  Management of Potential False Positive/False Negative/Indeterminate Results 10

Case and Contact Management .......................................................................................................................... 12
  Case and Contact Management Indicators ............................................................................................ 12

Case Management ......................................................................................................................................................... 13
  Case Isolation Period ............................................................................................................................................... 15
  Case Recovery and Post-Clearance ........................................................................................................... 19

Contact Management ................................................................................................................................................. 22
  Period of Communicability for Contact Follow-Up ........................................................................ 24
  Self-Isolation/Self-Monitoring for Contacts ......................................................................................... 26
  Use of Non-Medical Masks ............................................................................................................................... 32

Travelers from Outside of Canada .................................................................................................................... 36
  Contact tracing for airplane passengers ................................................................................................. 37

Tools ........................................................................................................................................................ 38

Additional Resources .................................................................................................................................................. 39

Document History .......................................................................................................................................................... 40
## List of Tables

<table>
<thead>
<tr>
<th>Table</th>
<th>Page #</th>
</tr>
</thead>
<tbody>
<tr>
<td>Table 1 – Testing Reference Documents</td>
<td>9</td>
</tr>
<tr>
<td>Table 2 – Managing Indeterminate Results</td>
<td>11</td>
</tr>
<tr>
<td>Table 3 – Start Date for Assessing Timing of Clearance for Asymptomatic Positives</td>
<td>18</td>
</tr>
<tr>
<td>Table 4 - Management of Cases after Clearance with New Symptoms, Exposures and/or Positive Test Results</td>
<td>21</td>
</tr>
<tr>
<td>Table 5 - Contact Follow-up when Case is Asymptomatic at Time of Positive Specimen Collection</td>
<td>25</td>
</tr>
<tr>
<td>Table 6 - Contact Management Based on Exposure Setting and Type</td>
<td>28</td>
</tr>
<tr>
<td>Table 7: Contact Self-Isolation and Self-Monitoring by Risk Level</td>
<td>33</td>
</tr>
<tr>
<td>Table 8: Managing Symptomatic Contacts</td>
<td>35</td>
</tr>
<tr>
<td>Table 9: Assessment and Management of Asymptomatic Travelers</td>
<td>37</td>
</tr>
</tbody>
</table>
Management of Cases and Contacts of COVID-19 in Ontario

Version 8 – June 23, 2020

This guidance document is not intended to take the place of medical advice, diagnosis or treatment. Where the document includes references to legal requirements, it is not to be construed as legal advice.

In the event of any conflict between this guidance document and any orders or directives issued by the Minister of Health or the Chief Medical Officer of Health (CMOH), the order or directive prevails.

- Please check the Ministry of Health (MOH) COVID-19 website regularly for updates to this document, mental health resources, and other information,
- Please check the Directives, Memorandums and Other Resources page regularly for the most up to date directives.

This document provides information for public health management of cases and contacts in Ontario. The MOH has developed this document with contributions from Public Health Ontario (PHO) based on current available scientific evidence and expert opinion. This document is subject to change as the situation with COVID-19 continues to evolve and as new tools/strategies to support public health management of cases and contacts are developed.

Nothing in this document is intended to restrict or affect the discretion of local medical officers of health to exercise their statutory powers under the Health Protection and Promotion Act. It is expected that all parties supporting case and contact management in Ontario will follow this guidance.


For detailed information on case and contact management within congregate settings, please reference the COVID-19 Guidance: Congregate Living for Vulnerable Populations. Additional resources for congregate living settings are available from Public Health Ontario.
Sector specific guidance documents also provide additional information about outbreaks in different settings (i.e., acute care, long-term care homes/retirement homes, workplaces, Emergency Child Care). These documents are available on the Ministry’s website.

This guidance document is being released as Ontario begins to enter Stage 2 of reopening, and a relaxation of some public health restrictions. As part of the gradual reopening of the province, it is critical that chains of illness are broken early and effectively – through strong case and contact management activities.

The changes made to this document incorporate many lessons learned from the initial response to COVID-19. The program is currently under review, with an eye to how to further strengthen the program and to create readiness for any future waves of COVID-19 and ensure a continued high quality of service is offered to the people of Ontario.

Case and Contact Management Responsibilities

Ministry of Health (MOH):

- Coordinate the provincial response to COVID-19.
- Support the coordination of complex case, contact and outbreak management activities, including access to specialized consultation and advice.
- Set provincial standards for case and contact management.
- Share information with the public.
- Report case details to the Public Health Agency of Canada (PHAC) as appropriate.
- Coordinate follow-up activities from the Self-Assessment Tool and the Canadian Border Services Agency.

All Public Health Units (PHUs):

- Review the case and contact management guidance in this document.
- Follow requirements of the Health Protection and Promotion Act, as well as related regulations.
- Conduct COVID-19 case management (for all probable and confirmed cases) as described in this document including: initial telephone calls to cases, daily monitoring of cases until cleared from self-isolation, and updating case status as required.
- Conduct COVID-19 contact management as described in this document including: ensuring that all new contacts are notified once identified, ensuring that there is appropriate follow-up and management for all close contacts of cases by:
  - Conducting daily monitoring for high-risk contacts
  - Verifying that high-risk contacts are compliant with self-isolation, and
  - Communicating MOH testing guidance to all contacts
- Track and report on own performance management indicators for case and contact management as described by the MOH.
- Ensure timely and complete data entry and reporting of case, contact and outbreak information.
- Identify to the MOH any capacity gaps (real or anticipated) and other challenges to meeting program standards via the Ministry Emergency Operations Centre (MEOC) (eocoperations.moh@ontario.ca).

Public Health Ontario (PHO):

- Participate in the MEOC’s response activities.
- Provide scientific and technical advice to stakeholders in areas such as laboratory testing, case and contact management information, reporting of case information using data entry in the integrated public health information system (iPHIS), outbreak management recommendations, and advice on clinical management and infection prevention and control (IPAC) & occupational health and safety (OHS) measures.
- Provide instruction on data entry of cases and contacts including but not limited to: updating and maintaining relevant iPHIS bulletins, enhanced surveillance directives, quick reference guide/iPHIS user guide.
- Conduct and disseminate provincial epidemiological surveillance and analyses.
- Provide laboratory testing for COVID-19, along with other laboratories in Ontario.
- Support PHUs as needed with case and contact follow-up and iPHIS data entry of cases.
Acute Care Settings:

- Acute care settings are responsible for monitoring close contacts who were exposed in the hospital and are currently admitted (i.e., inpatients), or were exposed in the community but are now admitted to hospital. This includes patients who were exposed in the emergency department and subsequently admitted. Acute care settings are also responsible for monitoring health care workers who were exposed at work.
- Acute care settings are not responsible for monitoring contacts of probable and confirmed cases in the community. This includes contacts who were exposed in an acute care setting or other health care setting (e.g., primary health care setting, urgent care clinic) but who are currently in the community and not hospitalized.
  - The responsibility for monitoring contacts that were exposed during their hospital admission (i.e., inpatients) and subsequently discharged prior to completing 14 days must be transferred from the acute care setting to the PHU.

Other Sectors:

- Other sectors also play a role in case and contact management including employers, congregate settings, primary care, assessment centres and education partners.
- Details around the role of these sectors can be found in existing guidance on the Ministry of Health website (outbreak guidance, sector specific guidance, etc)
- Work is ongoing to further refine the roles of these other sectors within the provincial case and contact management program.

Testing

PHUs must remain up to date on the latest provincial testing guidance. Table 1 outlines key documents/resources and their location. These documents are updated regularly.
### Table 1: Testing Reference Documents

<table>
<thead>
<tr>
<th>Document/Resource</th>
<th>Location</th>
<th>Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>Case Definition</td>
<td>MOH Guidance for Health Sector - [link]</td>
<td>The case definition is for surveillance purposes only.</td>
</tr>
<tr>
<td>Provincial Testing Guidance</td>
<td>MOH Guidance for the Health Sector - [link]</td>
<td>This document outlines provincial testing guidance including considerations for specific settings/groups.</td>
</tr>
<tr>
<td>Quick Reference PH Guidance on Testing and Clearance</td>
<td>MOH Guidance for the Health Sector - [link]</td>
<td>This document can help guide decision making on clearing/testing contacts of cases or individuals suspected or confirmed to have COVID-19</td>
</tr>
</tbody>
</table>

As of April 3, 2020, individuals who are tested are able to access their results online through the Ministry of Health online lab results viewer. Once the individual learns of their testing result, the portal also informs the individual about next steps. The MOH also recently launched Contact + for individuals who test positive. Contact + is integrated with the online lab results viewer and assists with initiating contact tracing efforts.

### Management of individuals awaiting testing results

- Symptomatic individuals should self-isolate
- Individuals who are contacts of a confirmed or probable case should self-isolate if they have had a high-risk exposure
- Asymptomatic individuals who did not have a high-risk exposure do not need to self-isolate while testing is pending
- Individuals awaiting testing results are not Probable cases. Test results should be obtained before deciding if the case is a confirmed case or does not meet the case definition.
Management of Potential False Positive/False Negative/Indeterminate Results

**False Positives:** A positive test should prompt the appropriate public health actions, even if being investigated as a potential false positive. If the test is thought to be a false positive due to concerns about the test validity, repeat the test.

Where true laboratory issues have been identified with previously issued positive results leading to an amended test result, follow PHO guidance on updating case status. See section on [Case Management](#) for further detailed guidance on the management of asymptomatic positive results with low pre-test probability.

**False Negatives:** A negative test may occur in an infected individual tested too early in their incubation period. Actions should not be made solely on the basis of a negative test result. False reassurance from a negative test is a concern. Where the clinical index of suspicion is high (e.g., based on clinical presentation and/or epidemiological context), a negative test does not rule out disease. For individuals with worsening/progressing symptoms, consider repeat testing. Individuals with an epidemiological link (e.g., exposure to a known case and/or outbreak) and test negative in their incubation period should continue their self-isolation or self-monitoring for the full 14 days.

**Investigations of Potential False Positive/False Negative Results:** Investigations should be done by the PHU and/or submitter in consultation with the testing laboratory. A review of the laboratory and epidemiological information of the case is necessary to inform the PHU and/or submitter on the public health and clinical management of the individual.

PHUs should consult PHO and/or the testing laboratory, for further interpretation of positive results where there is concern of a potential false positive. Different assays produce different results, have different limits of detection and different cutoff values for target detection. Values from one assay cannot be directly compared to another assay. Cycle threshold (Ct) or cycle number (CN) values may provide additional context in some situations, but require further interpretation based on the assay used and the clinical context of the patient.

**Indeterminate Results:** This may be due to low viral target quantity, or may represent a false signal. Of note, not all assays have an indeterminate range. For public health follow-up purposes, an indeterminate result in an individual with symptoms compatible with COVID-19 is sufficient laboratory criteria for a probable
case, and associated case and contact management practices. For clinical and public health purposes, indeterminate results may be investigated further but this is not routinely performed and will only be conducted for clinical and public health purposes at the request of the health care provider/PHU.

- An indeterminate result in an asymptomatic individual does not meet the probable case definition. Repeat testing should be considered if the individual has an epidemiological link (e.g., is a contact with high-risk exposure to a confirmed case or lives/works in a setting with an active outbreak), or if the individual develops symptoms compatible with COVID-19 after the initial test.

### Table 2: Managing Indeterminate Results

<table>
<thead>
<tr>
<th>Symptoms?</th>
<th>Epidemiological link?</th>
<th>Repeat Test Result</th>
<th>Management</th>
</tr>
</thead>
<tbody>
<tr>
<td>Yes/No</td>
<td>Yes/No</td>
<td>Positive</td>
<td>Manage as a confirmed case</td>
</tr>
<tr>
<td>Yes</td>
<td>Yes/No</td>
<td>Indeterminate</td>
<td>Manage as a probable case</td>
</tr>
<tr>
<td>Yes</td>
<td>No</td>
<td>Negative</td>
<td>No further management; Repeat test if symptoms worsen/progress</td>
</tr>
<tr>
<td>Yes/No</td>
<td>Yes</td>
<td>Negative</td>
<td>Continue self-isolation/self-monitoring (based on epidemiological link) until end of 14 days from last exposure; Repeat test if symptoms worsen/progress or develop symptoms (if asymptomatic)</td>
</tr>
<tr>
<td>Symptoms?</td>
<td>Epidemiological link?</td>
<td>Repeat Test Result</td>
<td>Management</td>
</tr>
<tr>
<td>----------</td>
<td>-----------------------</td>
<td>--------------------</td>
<td>------------</td>
</tr>
<tr>
<td>No</td>
<td>Yes</td>
<td>Indeterminate</td>
<td>Continue self-isolation/self-monitoring (based on epidemiological link) until end of 14 days from last exposure; Repeat testing if symptoms develop</td>
</tr>
</tbody>
</table>

## Case and Contact Management

The identification of a probable or confirmed COVID-19 case triggers an investigation by the PHU to assess potential exposures within the 14 days prior to symptom onset and to evaluate potential transmission among close contacts.

Public Health system capacity is an important criteria in decision making about other pandemic response activities (e.g., modification of public health measures). Resources are available to support PHUs with case and contact management, including a centralized workforce trained to conduct contact monitoring. PHUs who are or who anticipate they will experience capacity challenges in meeting case and contact management indicators are encouraged to contact the MEOC at (eocoperations.moh@ontario.ca).

## Case and Contact Management Indicators

The MOH is working to enhance the provincial case and contact management program, and has set certain indicators to ensure a full understanding of capacity issues/challenges and performance/success. Indicators are subject to change as the program evolves.

**Case Management Indicators:**

- % of cases are reached within 24 & 48 hours from when the PHU was notified of the case.

Currently the performance target for this indicator is that 90% of all cases are reached within 24 hours.
Contact Management Indicators:

- Number of newly identified contacts are successfully reached within 24 & 48 hours

Case Management

Instructions to manage a probable or confirmed case are outlined below. Case management instructions also apply to asymptomatic cases who test positive. For information on testing and diagnosis of asymptomatic individuals, PHUs should follow the guidance in the COVID-19 Quick Reference Public Health Guidance on Testing and Clearance document.

The PHU interviews the case and/or household contacts/family members (i.e. if the case is too ill to be interviewed, has died, or is a child) as soon as possible to collect the information for case data entry and identify contacts with high risk exposures.

- As per data entry guidance, the PHU will complete the “investigation start date” as well as the case “reported date” which is the date the case was reported to the PHU by the laboratory. This information will be used for ministry reporting on timeliness of case investigation initiation. The investigation start date is defined as the date the PHU first had contact with the case or proxy.

Most PHU investigators conduct these interviews by telephone, however for interviews conducted in person, the investigator follows Routine Practices and Contact, and Droplet Precautions when entering the case’s environment (see Guidance for Health Care Workers and Health Sector Employers for further information on OHS and IPAC measures).

For cases who are hospitalized or living in settings outside of an individual/family home, the PHU can provide advice and guidance from setting-specific guidance documents found on the MOH Guidance for the Health Sector website.

PHUs must follow 4 general steps as part of case management which are detailed below: initial case reporting, case exposure assessment, case status monitoring, and case contact assessment.
1. Initial Case Reporting

Only **Probable and Confirmed** cases are reportable to PHAC and to the World Health Organization. Within 24 hours of the identification of a **probable or confirmed** case in Ontario, the MOH will report the case to PHAC as part of the national notifiable disease reporting requirements, as well as in accordance with the International Health Regulations.

To meet this timeline, the PHU must enter the case into iPHIS (or equivalent local case management system) within 24 hours. The initial phone call to a confirmed case is to ensure the case is isolating and to gather information for entry into iPHIS. PHUs need to enter a minimum data set as dictated by the most recent Enhanced Surveillance Directive for each probable and confirmed case.

*Note: PHUs are no longer required to complete and submit the SARI case report form to PHO, however, this tool ([Appendix 1: Ontario’s Severe Acute Respiratory Infection Case Report Form](#)) may still be used to guide data collection and data entry.*

2. Case Exposure Assessment

PHUs must assess for relevant acquisition exposures in the 14 days prior to symptom onset (or 14 days prior to positive specimen collection date if never symptomatic) - see [Appendix 2](#) for a sample template. Ascertainment of exposures enables identification of locations/settings where transmission may be occurring, particularly if additional cases are associated with that location/setting. The most relevant acquisition exposures for entry are settings where the case spent the most time outside of the house. Potential settings include: a workplace; school/child care centre/camp; congregate living setting (including rooming house, hostel, bed and breakfast).

Data entry of exposures should follow data entry guidance by PHO.

3. Case Status Monitoring

Cases must be monitored daily for assessment of the illness, to ensure ability to comply with self-isolation, and to determine when they can be cleared from self-isolation - see [Appendix 3](#) and [Appendix 4](#) for a sample template. At a minimum, cases must be called on the phone within 24 hours from when the PHU was notified of the case, as well as on day 7 and day 14 of the isolation period. Methods of contact on the other days of self-isolation can include texts, emails or phone calls.
The determination of how to make contact on these days can be based on both PHU discretion, and the preference of the case. Ongoing communication may be required if the case is not cleared by day 14.

4. **Case Contact Assessment**

PHUs must conduct contact tracing activities (see [Contact Management](#)) to identify close contacts of probable or confirmed cases with high-risk exposures - see [Appendix 5](#) for a sample worksheet to conduct close contact tracing activities. In addition, PHUs should ask about any identifiable groups of low-risk contacts to inform consideration of targeted group communication as outlined in Table 7. PHUs should ask the case about any other prompts they have received to initiate the process of contact tracing (such as Contact +), any information received at an Assessment Centre, or from another care provider. PHUs must assess contacts based on exposure setting and risk of exposure based on the interaction with the case.

**Case Isolation Period**

Guidance for recommendations on isolation measures for probable and confirmed cases of COVID-19 is detailed in [Appendix 7](#). Detailed guidance on clearance from isolation is found in the [COVID-19 Quick Reference Public Health Guidance on Testing and Clearance](#) document.

For cases who are **symptomatic at/around the time of their positive result**, their isolation period is based on their symptom onset date.

**Asymptomatic Cases**- A positive result in an asymptomatic individual is a confirmed case. Asymptomatic individuals may be tested for a variety of reasons under the provincial testing guidance, including for surveillance / targeted testing purposes, and may represent a recent infection that is currently infectious, or a more remote infection that is no longer infectious. (For guidance on potential false-positive laboratory results, see above Management of Potential False Positive/False Negative/ Indeterminate results. For guidance on re-positives, see Case Recovery and Post-Clearance).

For each case who was asymptomatic at or around the time of their first positive COVID-19 test result, PHUs should assess the pre-test probability of current, infectious COVID-19 (i.e., low vs. medium/high pre-test probability).
Assessment of pre-test probability should take into account the clinical and epidemiological context of the case that will guide the level of case and contact management required. For example, asymptomatic cases tested as a contact of a case or as part of an outbreak investigation have a higher pre-test probability; whereas, an asymptomatic case tested as part of routine surveillance testing and who has no known exposures or symptoms has a lower pre-test probability.

Specific factors that should inform assessment of pre-test probability of current, infectious COVID-19 in asymptomatic cases include:

- Symptom history, i.e., a prior history of symptoms compatible with COVID-19 that increases the likelihood of prior infection;
- Reason for testing (i.e., symptoms / epidemiological link vs. surveillance / targeted testing campaign / other);
- Epidemiological links (i.e., high-risk exposure to a known probable or confirmed case of COVID-19, or to a known COVID-19 outbreak) in the potential acquisition period;
- Local epidemiology of COVID-19 in regions where the case may have had high-risk exposures in the potential acquisition period (including, if applicable, other targeted/surveillance testing results);
- Risk behaviours of the case in the potential acquisition period (e.g., circle of close contacts, activities outside of the home), if/as appropriate.

**Asymptomatic Cases with a Medium/High Pre-Test Probability** - Asymptomatic cases assessed as having a medium/high (i.e., not low) pre-test probability of having current, infectious COVID-19 due to recent infection include, at minimum, case who were tested as a result of an epidemiological link to a known COVID-19 case or a known COVID-19 outbreak, or both. These cases should be managed as potentially infectious, and isolated for 14 days following the positive specimen collection date if they remain asymptomatic. **Re-testing is not indicated**, as a negative repeat test would not change public health management of the case or contacts.

If symptoms develop within 4 days of the specimen collection date, this would extend the case’s isolation period for at least 14 days from symptom onset (see Testing and Clearance guidance document for details). This is based on a typical period of positivity prior to symptom onset is 2-3 days. However, discretion may be applied to extend the isolation period based on symptoms starting ≥4 days after positive specimen collection date, as case reports have found positive results in pre-symptomatic individuals as much as 6 days prior to symptom onset.
Health Care Workers require an individual assessment, and should not automatically be assumed to be a medium/high pre-test probability. See Table 3 (below) for additional guidance on start date for assessing timing of clearance for asymptomatic positives with medium/high pre-test probability of having infectious COVID-19 due to recent infection.

**Asymptomatic Cases with Low Pre-Test Probability** - asymptomatic cases who are assessed as having a **low pre-test probability** of being a case that is currently infectious (which, as above, excludes those with an epidemiological link to a known COVID-19 case or outbreak) should have a **repeat test** (as soon as possible) to guide further case and contact management. This may include individuals who are part of a targeted asymptomatic testing campaign (for example as part of a workplace testing campaign).

**Repeat Test Result:**

- **Positive/Repeat Test Not Available:** Manage the case as if currently infectious.
  - Isolate case for 14 days from **first** positive specimen collection date
  - Initiate Contact Management as usual.
- **Negative:** Manage as prior infection that is no longer infectious with ongoing detection of viral RNA near the limit of detection.
  - Case can stop isolating after negative test
  - As it is often not possible to determine when the case was infectious, contact follow-up is at the discretion of the PHU.

Of note, SARS-CoV-2 RNA has been detected in specimens collected 3-4 weeks after symptom onset; however, viral detection has also been identified in some cases well beyond 4 weeks (>70 days) in some cases.

See Table 3 below for assessing timing of clearance for cases with low pre-test probability of having infectious COVID-19, where repeat testing is positive/not available.
<table>
<thead>
<tr>
<th>Symptoms compatible with COVID-19?</th>
<th>Known epidemiological link (e.g., close contact exposure) prior to symptom onset?</th>
<th>Start date for assessing timing of clearance</th>
</tr>
</thead>
<tbody>
<tr>
<td>Symptoms at/around time of positive specimen collection date</td>
<td>Yes or No</td>
<td>Symptom onset date</td>
</tr>
<tr>
<td>Symptoms &gt;4 weeks prior to positive specimen collection date¹</td>
<td>Yes or No</td>
<td>Positive specimen collection date</td>
</tr>
<tr>
<td>Symptoms ≤ 4 weeks prior to positive specimen collection date¹</td>
<td>Yes</td>
<td>Symptom onset date</td>
</tr>
<tr>
<td>Symptoms ≤ 4 weeks prior to positive specimen collection date¹</td>
<td>No</td>
<td>Positive specimen collection date</td>
</tr>
<tr>
<td>Symptoms &lt;4 days after positive specimen collection date²</td>
<td>Yes or No</td>
<td>Symptom onset date</td>
</tr>
<tr>
<td>Symptoms ≥4 days after positive specimen collection date²</td>
<td>Yes or No</td>
<td>Positive specimen collection date</td>
</tr>
<tr>
<td>Never symptomatic</td>
<td>Yes or No</td>
<td>Positive specimen collection date</td>
</tr>
</tbody>
</table>

1. SARS-CoV-2 RNA has been detected in specimens collected 3-4 weeks after onset; however, viral detection has also been identified in some cases well beyond 4 weeks (>70 days) in some cases. Assessing symptoms reported >4 weeks prior to first positive test date will have a greater degree of uncertainty as to whether they were related to the current
positive test. Discretion may be applied if there is a known epidemiological link prior to symptoms >4 weeks from first positive specimen date.

2. Typical period of positivity prior to symptom onset is 2-3 days. Case reports have found positive results in pre-symptomatic individuals as much as six days prior to symptom onset. Discretion may be applied to extend isolation period based on symptoms starting ≥4 days after positive specimen collection date.

**Case Recovery and Post-Clearance**

Guidance for management of cases is detailed in [Appendix 7](#).

Once a case is **cleared from isolation** based on the [COVID-19 Quick Reference Public Health Guidance on Testing and Clearance](#) document, **self-isolation, and Droplet and Contact measures where applicable, can be discontinued.**

At this time, there is no evidence of re-infection from COVID-19, and limited information on immunity after infection. However, it is known that confirmed cases may continue to test positive, even after clearance and/or negative results, for several weeks after infection.

- Confirmed cases should generally **not** be re-tested within 90 days of clearance, as positive results after clearance are not uncommon.
  - Clinical discretion should be used to consider re-testing if new onset of symptoms occur within 90 days after clearance.
- PHUs may consult with the testing laboratory with respect to the details of the positive test result relative to the cut-off values of the test. However, there is no definitive Ct value that indicates viability of virus, and Ct values and cut-offs vary by assay and laboratory.
- Cases who happen to test positive within 90 days after clearance are generally not considered infectious, do not need to re-isolate, and do not require contact follow-up. See below for scenarios where case follow-up may be warranted with a positive result after clearance.
  - Cases who are immunocompromised may theoretically be more likely to have prolonged detection of virus, but evidence is limited as to whether it represents viable virus that warrants re-isolation.
- PHUs must follow data entry guidance for any positive results after clearance, including identifying the case as a “RE-POSITIVE”, entering laboratory and case details. PHUs should not enter a new case encounter for the individual.
- At this time, there is no case definition for ‘re-infection’ for COVID-19
If a previously cleared case presenting with a risk for “re-infection” PHUs should notify PHO (epir@oahpp.ca) for case consultation and further investigation:

- New onset of symptoms compatible with COVID-19 after a new high-risk exposure to a case; OR
- New positive result > 90 days after clearance

Due to uncertainty regarding immunity after infection, recovered individuals should still take the same precautions as someone who has never had COVID-19 in terms of avoiding exposure due to theoretical risk of re-infection in the future. This includes:

- Following physical distancing advice
- Following advice for HCWs for Personal Protective Equipment in Directives #1, 2, and 3 (as applicable)
- Self-isolating for 14 days after a NEW high risk exposure to a new unrelated case.
  - This does not apply to post-clearance exposures to related cases, such as cases within the same household or outbreak scenario. For example, in a long-term care home outbreak, if a cleared resident is exposed to a case within the outbreak, they do not need to re-isolate.
- Previously cleared cases with a new positive result who are immunocompromised, and had a new high risk exposure prior to symptom onset, or a new positive result >90 days after clearance, should self-isolate until further laboratory and epidemiological investigation is available to assess the case (e.g., Ct value, repeat testing, exposure assessment)
  - Although resolved cases should generally not be re-tested post-clearance, clinical discretion should be used to consider re-testing if new onset acute symptoms occur up to 90 days after clearance.
Table 4: Management of Cases after Clearance with New Symptoms, Exposures and/or Positive Test Results

Please note that this does not apply to COVID-19 cases known to be immunocompromised.

<table>
<thead>
<tr>
<th>New Symptom Onset?</th>
<th>New High-Risk Exposure?</th>
<th>Laboratory Results</th>
<th>Public Health Management</th>
</tr>
</thead>
<tbody>
<tr>
<td>No</td>
<td>No</td>
<td>Positive specimen within 90 days of clearance (not generally recommended to re-test, but may occur inadvertently)</td>
<td>Flag case as “RE-POSITIVE”; No case isolation; No contact management</td>
</tr>
<tr>
<td>Yes/No</td>
<td>Yes/No</td>
<td>Positive specimen &gt;90 days after clearance</td>
<td>Notify PHO (<a href="mailto:epir@oahpp.ca">epir@oahpp.ca</a>) for case consultation; Flag case as “RE-POSITIVE”; Case isolation until further laboratory/epidemiological investigation; No contact management until further investigation</td>
</tr>
<tr>
<td>Yes</td>
<td>Yes</td>
<td>Positive specimen within 90 days of clearance</td>
<td>Notify PHO (<a href="mailto:epir@oahpp.ca">epir@oahpp.ca</a>) for case consultation; Flag case as “RE-POSITIVE”; Case isolation until further laboratory/epidemiological investigation; No contact management until further investigation</td>
</tr>
<tr>
<td>New Symptom Onset?</td>
<td>New High-Risk Exposure?</td>
<td>Laboratory Results</td>
<td>Public Health Management</td>
</tr>
<tr>
<td>--------------------</td>
<td>-------------------------</td>
<td>--------------------</td>
<td>-------------------------</td>
</tr>
<tr>
<td>Yes</td>
<td>No</td>
<td>Positive specimen within 90 days of clearance</td>
<td>Flag case as “RE-POSITIVE”; Isolate until 24 hours after symptom improvement; No contact management;</td>
</tr>
<tr>
<td>No</td>
<td>Yes (new high-risk exposure to unrelated case)</td>
<td>N/A (repeat testing not recommended if asymptomatic)</td>
<td>Self-isolate (as a contact) for 14 days from last exposure to case; Clinical discretion to re-test if develop symptoms</td>
</tr>
</tbody>
</table>

**Contact Management**

The PHU should consult Table 6 to determine the exposure risk level of each contact of a COVID-19 case and Table 7 to determine the follow-up public health actions.

- A close contact is defined as **an individual with a high-risk exposure to a confirmed or probable case**.

PHUs must follow the guidance below when making initial contact, as well as for subsequent follow-up.

1. **Initial Contact**

The PHU provides an introduction and informs the contact of complete confidentiality of the interview process. In addition, the PHU provides information on resources available to support self-isolation or self-monitoring activities.

The PHU must recommend testing and ensure access to testing for:

- all high-risk exposure contacts regardless of symptoms, and
- all symptomatic contacts with a low-risk exposure
Where identifiable, PHUs must conduct an initial phone call within 24 hours of becoming aware of a low-risk contact, to ensure the individual is aware of how to self-monitor.

**Testing of Asymptomatic High-Risk Contacts**

Asymptomatic high-risk contacts should be tested within their self-isolation period (as per the [Provincial Testing Guidance](#)). Testing after the end of their self-isolation period is not recommended. Timing of testing should consider over what period exposure occurred and if the contact may have been exposed at the same time as the case (i.e., potential the contact is a co-primary asymptomatic case). The median incubation period is approximately 5 days.

If the contact may be a co-incident case, or even the index case to the known case, testing earlier in the incubation period allows earlier identification of the contact as a case, and initiation of their public health management. However, a negative result early in the incubation period can result in contacts refusing to maintain quarantine after false reassurance from a negative test. Negative tests later in the incubation period may be more reassuring that transmission has not occurred so far; however, a positive test later in the incubation period results in delayed management of the contact as a case.

Close contacts with high risk exposures must be advised that negative results within their 14 day incubation period **do not change** their self-isolation requirements, as they may still be incubating. Contacts who test positive should be managed as confirmed cases. High-risk contacts who test negative and remain asymptomatic do not need to be re-tested in their self-isolation period unless they develop symptoms.

While asymptomatic contacts with low-risk exposures are not advised to test unless they become symptomatic, if they happen to test negative in their incubation period, they should be advised to continue to self-monitor for the remainder of their 14 day period.

All contacts must be informed of how to contact the PHU if they develop symptoms or have other questions. The PHU must advise contacts to call 911 if they require emergency care and inform paramedic services or health care provider(s) that they are a contact of a COVID-19 case.
2. Subsequent Follow-Up

The PHU may use the Close Contact Daily Clinical Update Form in Appendix 6 to monitor high risk contacts. The PHU should actively monitor (daily) any symptomatic contacts who are waiting on test results.

As part of daily contact assessments for high-risk exposures, the PHU must assess:

- Onset of symptoms since last assessment
- Reported compliance with self-isolation; and
- Needs in order to comply with self-isolation, referring supports as required to help to enable successful isolation.

**Low risk contacts:** Based on the initial assessment of the needs of the contact, further follow-up with the contact may be required throughout the self-monitoring period.

**Period of Communicability for Contact Follow-Up**

Cases who were symptomatic at/around the time of positive specimen collection – contact tracing extends from 48 hours prior to symptom onset to when the case began self-isolating (or was cleared from isolation if never self-isolated).

For cases who were asymptomatic at the time of positive specimen collection date, Table 5 below can be referenced.
Table 5: Contact Follow-up when Case is Asymptomatic at Time of Positive Specimen Collection

<table>
<thead>
<tr>
<th>Symptom Onset</th>
<th>Contact Tracing Period</th>
<th>Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>Case had no symptoms at/around time of testing</td>
<td>Extends from 48 hours prior to positive specimen collection to date to when case began self isolating.</td>
<td>If asymptomatic case with a low pre-test probability has a negative repeat test, contact follow-up is at the discretion of the PHU as it is not possible to determine when the case may have been infectious.</td>
</tr>
<tr>
<td>Case’s symptoms resolved prior to specimen collection date and case has a known high-risk exposure in 14 days prior to symptom onset</td>
<td>Extends from 48 hours prior to symptom onset to when case began self-isolating (or was cleared from isolation if never self-isolated).</td>
<td>For symptoms that occurred &gt;4 weeks prior to specimen collection date, or where there is uncertainty about the relatedness of prior symptoms to the current positive test result, extending contact follow-up to 48 hours prior to symptom onset date is at the discretion of the PHU.</td>
</tr>
<tr>
<td>Symptoms develop after positive specimen collection date</td>
<td>Extends from 48 hours prior to positive specimen collection date to when case began self-isolating (or was cleared from isolation if never self-isolated).</td>
<td></td>
</tr>
</tbody>
</table>
Self-Isolation/Self-Monitoring for Contacts

While the isolation of asymptomatic contacts is technically termed “quarantine”, the common use of “self-isolation” to refer to both symptomatic and asymptomatic individuals means we have adopted the language of “self-isolation” for asymptomatic close contacts for ease of understanding.

The purpose of self-isolation is to prevent the risk of spread in the event a contact becomes infected and prior to recognizing they are infectious. Due to varying degrees of risk posed by different exposures, contacts can be categorized into two levels of risk exposure and corresponding requirements for self-isolation: high-risk, and low-risk contacts. **Only individuals with high-risk exposures are considered close contacts.**

- **Table 6** details contacts by their exposure setting and exposure type.
- **Table 7** details description of required PHU follow-up.

The period of self-isolation or self-monitoring is 14 days (maximum incubation period) following last known unprotected exposure to an infectious case. This should be based on the earlier date of when the case self-initiated self-isolation or was advised to self-isolate by the PHU.

**Household, or similar, contacts** with ongoing exposure to the case:

- Cases should self-isolate as much as possible within the household, and wear a mask when physical distancing is not possible in the home.
- Where self-isolation is not possible within the household, consider alternate living arrangements for the case or contacts to reduce risk of transmission.
- Where alternate living arrangements are not available, last date of exposure to the case should be based on the date the case was advised to start self-isolating by the PHU (rather than using the end of the case’s infectious period as the date of the last exposure).
  - Where there are shared common spaces/kitchen/bathroom, self-isolation is maintained if physical distancing (or mask use when <2m) and appropriate environmental cleaning is in place (e.g. of high-touch surfaces).
  - Emerging evidence suggests COVID-19 is spread mainly from person-to-person. It may be possible that a person can get COVID-19 by touching a surface or object that has the virus on it and then touching their own mouth, nose, or possibly their eyes; however, this is not thought to be the main way the virus spreads.
• If additional members of the household become ill, asymptomatic household members generally do not need to extend their period of self-isolation based on last exposure to the new case, as the presumption is that everyone in the household was exposed at the same time to the first case, subsequent cases are associated with the same original exposure, and household members are maintaining their own self-isolation as close contacts. In some circumstances (e.g. parent/child cases) where there has been significant ongoing exposure to subsequent cases, asymptomatic household contacts may be advised to extend self-isolation based on a risk assessment of exposure to the new case in the household. Asymptomatic household members generally do not need to be re-tested based on exposure to the second case, if they have already been tested after exposure to the first case, but may be advised to re-test based on the risk assessment.
Table 6: Contact Management Based on Exposure Setting and Type

<table>
<thead>
<tr>
<th>Exposure Setting</th>
<th>Exposure Type</th>
<th>Exposure Risk Level</th>
</tr>
</thead>
<tbody>
<tr>
<td>Household</td>
<td>• Anyone living in the same household, while the case was not self-isolating and infectious:</td>
<td>High risk exposure – self-isolate</td>
</tr>
<tr>
<td>(includes other</td>
<td>o This may include members of an extended family, roommates, boarders, ‘couch surfers’ etc.</td>
<td></td>
</tr>
<tr>
<td>congregate</td>
<td>o This may include people who provided care for the case (e.g., bathing, toileting, dressing, feeding etc.)</td>
<td></td>
</tr>
<tr>
<td>settings)</td>
<td>o This may include congregate settings (e.g., dormitories, shelters, group homes, detention centres, child/daycare centres) where direct contact (&lt;2 meter) is occurring in shared rooms/living spaces (Follow Ministry of Health guidance for outbreak management in congregate living settings; if an outbreak is declared, outbreak measures should guide contact management).</td>
<td></td>
</tr>
<tr>
<td></td>
<td>▪ This includes household contacts as above who only had exposure to the case after the case started self-isolating, if this is supported by a risk assessment.¹</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Household contacts as above who only had exposure to the case while the case was self-isolating and applying consistent and appropriate precautions (i.e., physical distancing, hand hygiene, use of mask when unable to physically distance). Shared use of bathroom/kitchen while maintaining physical distancing and frequent environmental cleaning would not be considered inappropriate precautions.</td>
<td>Low risk exposure – self-monitor</td>
</tr>
<tr>
<td>Exposure Setting</td>
<td>Exposure Type</td>
<td>Exposure Risk Level</td>
</tr>
<tr>
<td>------------------</td>
<td>---------------</td>
<td>---------------------</td>
</tr>
</tbody>
</table>
| Community/Workplaces | • Had direct contact with infectious body fluids of the case (e.g., coughed on or sneezed on)  
• Had close (<2m) prolonged unprotected contact  
• Had prolonged unprotected contact but only while the case was consistently physically distancing (e.g., attendees at a gathering, co-workers in a common work area).  
• Only transient interactions (e.g., walking by the case or being briefly in the same room) | High risk exposure – self-isolate  
Low risk exposure – self-monitor |
| Healthcare (including all locations where health care is provided, e.g., community, acute care, long-term care) | **Patient is the case:**  
• HCW and/or support staff who provided direct care for the case, or who had other similar close physical contact (i.e., < 2 metres from patient for any duration of time) **without** consistent and appropriate use of personal protective equipment\(^3\) in relation to the care provided.  
• Other patients in the same room when the case **was not** on Droplet and Contact precautions  
• Other patients in waiting room/common areas (i.e., < 2 metres from case for any duration of time) when the case **was not wearing** a surgical/procedure mask | High risk exposure – self-isolate  
(or work self-isolation if critical to operations) |
| Healthcare (including all locations where health care is provided, e.g., community, acute care, long-term care) | **HCW is the case:**  
• All patients for whom the HCW provided direct care, or who had other similar close physical contact (i.e., patient was < 2 metres away from HCW for any duration of time), when the HCW **was not wearing** a surgical/procedure mask  
• All co-workers who had close prolonged unprotected contact\(^2\) with the HCW (e.g., within 2 metres in an enclosed common area when the HCW **was not wearing** a surgical/procedure mask) | High risk exposure – self-isolate  
(or work self-isolation if critical to operations) |
<table>
<thead>
<tr>
<th>Exposure Setting</th>
<th>Exposure Type</th>
<th>Exposure Risk Level</th>
</tr>
</thead>
</table>
| Healthcare (including all locations where health care is provided, e.g., community, acute care, long-term) | **Patient is the case:**  
- Healthcare worker and/or support staff who provided direct care for the case, or who had other similar close physical contact (i.e., < 2 metres from patient for any duration of time) **with** consistent and appropriate use of PPE in relation to the care provided | Low risk exposure – self-monitor |
| | **HCW is the case:**  
- All patients for whom the HCW provided direct care, or who had other similar close physical contact (i.e., patient was < 2 metres away from HCW for any duration of time), when the HCW **was wearing** a surgical/procedure mask  
- All co-workers who had close prolonged contact1 with the HCW (e.g., within 2 metres in an enclosed common area when the HCW **was wearing** a surgical/procedure mask) | Low risk exposure – self-monitor |
| |  
- Laboratory worker processing COVID-19 specimens from case **without** appropriate PPE (including accidental exposures where appropriate PPE was breached).³ | High risk exposure – self-isolate (or work self-isolation if critical to operations) |
| |  
- Laboratory worker processing COVID-19 specimens from case **with** appropriate PPE.³ | Low risk exposure – self-monitor |
<table>
<thead>
<tr>
<th>Exposure Setting</th>
<th>Exposure Type</th>
<th>Exposure Risk Level</th>
</tr>
</thead>
</table>
| Conveyance (e.g., aircraft, train, bus) | • Passengers or crew seated within 2 meters of the case (approximately two seats in all directions, depending on type of aircraft/conveyance and seating) while the case was not wearing a surgical/procedure mask  
  • Other passengers/crew with close prolonged\(^2\) contact while case was not wearing a surgical/procedure mask or direct contact with infectious body fluids | High risk exposure – self-isolate |
|                  | • Passengers or airplane crew seated within 2 meters of the case (approximately two seats in all directions, depending on type of aircraft and seating) while the case was wearing a surgical/procedure mask  
  • Other passengers/crew with close prolonged\(^2\) contact while case was wearing a surgical/procedure mask | Low risk exposure – self-monitor |
|                  | • Crew members who do not meet criteria above                                                                                                                                                                | Low risk exposure – self-monitor |
|                  | • Other passengers seated elsewhere in cabin/car as case who do not meet above criteria.                                                                                                                                 | Low risk exposure – self-monitor |
| Travel to affected area | • Exposure by travelling outside of Canada in past 14 days\(^4\)                                                                                                                                              | High risk exposure – self-isolate |

\(^1\) Based on an individual risk assessment, it may be reasonable to consider household contacts who only had exposure after the case was self-isolating as having low-risk exposures, if the PHU is confident that consistent and appropriate physical distancing, hand hygiene, and environmental cleaning is in place (e.g., frequent cleaning of shared bathroom/kitchen, if applicable). If assessed has having low-risk exposure, self-monitoring rather than self-isolation would be required (see Table 6 for details).

\(^2\) As part of the individual risk assessment, consider the duration and nature of the contact’s exposure (e.g., a longer exposure time/cumulative time of exposures likely increases the risk, an outdoor only exposure likely decreases the risk, whereas exposure in a small, closed, or poorly ventilated space may increase the risk), the case’s symptoms (coughing or severe illness likely increases exposure risk) and whether personal protective equipment
(e.g., procedure/surgical mask) was used. To aid contact follow-up prioritization, prolonged exposure duration may be defined as lasting more than 15 minutes; however, data are insufficient to precisely define the duration of time that constitutes a prolonged exposure, and exposures of <15 minutes may still be considered high risk exposures depending on the context of the contact/exposure.

3 Refer to relevant guidance for health care professionals on what constitutes appropriate PPE for the type of interaction with the case. PHO IPAC guidance on PPE

4 Health Care Workers returning from travel should not attend work if they are sick. If there are particular workers who are deemed critical, by all parties, to continued operations, these workers undergo regular screening, use appropriate Personal Protective Equipment (PPE) for the 14 days and undertake active self-monitoring. This includes taking their temperature twice daily to monitor for fever, and immediately self-isolate if symptoms develop and self-identify to their occupational health and safety department.

**Use of Non-Medical Masks**

Non-medical masks may be used in non-health care settings for source control and prevention. However, there is insufficient evidence to inform whether or to what degree they alter the risk to contacts from a confirmed case given the variability in the types of non-medical masks used, and the appropriateness/consistency of use by the wearer in the community. In general, the use of non-medical masks by a case or their contact does not alter the risk assessment of contacts in Table 6. Use of medical (surgical/procedure) masks by cases/contacts in non-healthcare settings may be considered for adjusting risk assessment, depending on appropriateness/consistency of use by the wearer.
Table 7: Contact Self-Isolation and Self-Monitoring by Risk Level

Note: If an outbreak is declared (e.g., in a workplace, congregate living setting, long-term care home, acute care, child care), relevant Ministry of Health guidance on outbreak measures apply and should guide management of contacts and may exceed recommendations for low-risk contacts of non-outbreak cases listed here:

<table>
<thead>
<tr>
<th>Category</th>
<th>Actions for the Individual</th>
<th>Public Health Monitoring/Activities</th>
</tr>
</thead>
<tbody>
<tr>
<td>High risk exposure</td>
<td>Self-Isolate:</td>
<td>Initial contact (e.g., by phone) to provide information on self-isolation and who to call if become symptomatic</td>
</tr>
<tr>
<td></td>
<td>• Do not attend school or work</td>
<td>Daily monitoring is required. Phone calls are required at the beginning, middle and end of the self-isolation period (e.g., days 1, 7 and 14). Contact on the other days can be via email/text/phone at discretion of PHU and based on preference of contact.</td>
</tr>
<tr>
<td></td>
<td>• Avoid close contact with others, including those within your home, as much as possible</td>
<td>Consider providing thermometer or assessing other needs/supports to facilitate self-isolation and monitoring of symptoms</td>
</tr>
<tr>
<td></td>
<td>• Follow advice in self-isolation fact sheet</td>
<td>Provide handouts:</td>
</tr>
<tr>
<td></td>
<td>• Have a supply of procedure/surgical masks available should close contact with others be unavoidable</td>
<td><strong>Self-isolation</strong></td>
</tr>
<tr>
<td></td>
<td>• Postpone elective health care until end of monitoring period</td>
<td>Ensure contact is advised of recommendation for asymptomatic testing within their self-isolation period (based on availability of testing)</td>
</tr>
<tr>
<td></td>
<td>• Use a private vehicle if need to attend a medical appointment. Where a private vehicle is not available, private hired vehicle may be used while wearing a procedure/surgical mask and sitting in the rear passenger seat with the window open (weather permitting). Do not take public transportation.</td>
<td>Ensure contact is advised of recommendation for re-testing if contact reports symptoms (based on availability of testing), and manage as a probable case if testing is refused/cannot be performed</td>
</tr>
<tr>
<td></td>
<td>• Remain reachable for daily monitoring by local PHU</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Discuss any travel plans with local PHU</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• If symptoms develop, ensure self-isolating immediately, and contact local PHU and health care provider prior to visiting a health care facility</td>
<td></td>
</tr>
<tr>
<td>Category</td>
<td>Actions for the Individual</td>
<td>Public Health Monitoring/Activities</td>
</tr>
<tr>
<td>--------------------</td>
<td>-------------------------------------------------------------------------------------------</td>
<td>-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------</td>
</tr>
</tbody>
</table>
| Low risk exposure  | Follow guidance on core public health measures recommended for everyone at all times including:  
  - Self-monitoring for symptoms of COVID-19,  
  - Seeking [assessment and testing](https://example.com), and  
  - Self-isolating if symptoms develop, as per provincial guidance. | Where identifiable (for example: low risk household contacts), PHUs must conduct an initial phone call within 24 hours of becoming aware of the contact, to ensure the individual is aware of how to self-monitor.  
  Based on the initial assessment of the needs of the contact, further follow-up with the contact may be required.  
  Where individuals self-identify to the PHU with information that indicates a possible high-risk exposure, the PHU must conduct an individual-level risk assessment.  
  Communications to low risk individuals/groups must include information about symptoms, self-monitoring, how to self-isolate if symptoms develop and how to contact the local PHU. This should include:  
  - Information on [Self-monitoring](https://example.com),  
  - Emphasizing need to be able to self-isolate immediately and seek testing if symptoms develop.  
  - Advising HCWs to inform their employer/institution of their exposure.  
  Where identifiable individuals/groups with low-risk contact are known to the PHU, the PHU must provide targeted and timely communication to low risk contacts such as:  
  - working with employers to send a letter to co-workers/clients in the same area in the workplace;  
  - working with community/religious leaders to inform other attendees of community activities/services;  
  - household contacts of cases with exposure only after the case was self-isolating consistently and appropriately (if assessed as low risk exposures).  
  This does not include notifying stores/services where the case was shopping/picking up items/had brief interactions and physically distancing with other customers/staff. |
### Table 8: Managing Symptomatic Contacts

<table>
<thead>
<tr>
<th>Exposure Type</th>
<th>Testing Result</th>
<th>Instructions for PHU</th>
</tr>
</thead>
<tbody>
<tr>
<td>High-Risk</td>
<td>Negative</td>
<td>Continue managing as high-risk exposure contact including advising continued self-isolation until 14 days from last exposure. Facilitate re-testing if symptoms worsen or progress.</td>
</tr>
<tr>
<td></td>
<td></td>
<td><strong>Never Tested (ie. Refused testing)</strong> Manage as probable case including case and contact management.</td>
</tr>
<tr>
<td>Low-Risk</td>
<td>Negative</td>
<td>While asymptomatic contacts with low-risk exposures are not advised to test unless they become symptomatic (as per MOH testing guidance for the general public), if they happen to test negative in their incubation period, they should be advised by the testing facility to continue to follow guidance on core public health measures recommended for everyone at all times, including:</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Self-monitoring for symptoms of COVID-19,</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Self-isolating if symptoms develop; and</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Seeking <a href="#">assessment and testing</a></td>
</tr>
<tr>
<td></td>
<td></td>
<td>If the PHU happens to be aware of these individuals, they may re-inforce messaging.</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Advise re-testing if symptoms worsen or progress.</td>
</tr>
<tr>
<td></td>
<td></td>
<td><strong>Never Tested</strong> Not applicable, as no individual follow up, and PHU unlikely to be aware of this situation. If the PHU happens to be aware of these individuals, they must re-inforce that symptomatic individuals should be tested.</td>
</tr>
</tbody>
</table>
Travelers from Outside of Canada

On March 26, 2020, the Government of Canada has put emergency measures in place that require a mandatory 14-day self-isolation (or quarantine period) for returning travelers from outside of Canada.

All individuals permitted to enter Canada are subject to this Order, with the exception of certain persons who cross the border regularly to ensure the continued flow of goods and services, and those who provide essential services.

**Essential Service Workers** returning from any destination outside of Canada are not required to self-isolate upon their return from travel providing they are asymptomatic. These workers should self-monitor for symptoms and immediately self-isolate should symptoms develop.

HCWs are not required to self-isolate after travel, however it is strongly recommended that they do so for 14 days upon return, wherever possible. If an HCW is required to work within 14 days of returning from travel, they may do so with specific precautions. Refer to the [How to Self-isolate while Working fact sheet](#).

All incoming travellers, at point of entry, are required to provide their contact information and where they are staying. They also must inform the officer if they have symptoms.

Oversight and enforcement of these orders is being done by Peace Officers and the Royal Canadian Mounted Police (RCMP), and will include random touch points with returning travellers to ensure compliance. At this time, local PHUs do not have a direct role in enforcement of the Quarantine Orders but are able to provide support and information (e.g., requirements of self-isolation).

Should an individual subject to a federal quarantine order require non-COVID related health care outside of a federal quarantine facility (e.g., if transfer from a federal quarantine facility to a local hospital is required, during the quarantine period), these individuals should be managed as having a high risk exposure requiring isolation. They should be managed in consultation with the local PHU and local health care providers, including IPAC.
Table 9: Assessment and Management of Asymptomatic Travelers

<table>
<thead>
<tr>
<th>Travel outside of Canada in the past 14 days</th>
<th>Consider as 'High risk exposure'. Follow Table 7 – 'High risk exposure'</th>
</tr>
</thead>
<tbody>
<tr>
<td>Travel within Canada</td>
<td>If any individuals have COVID-19 exposure concerns and self-identify to their PHU as having traveled within Canada, the PHU should assess the individual’s exposure history to determine whether they should be managed as a high, or low risk exposure contact, as per Table 6.</td>
</tr>
</tbody>
</table>

Any returning travelers who develop symptoms should follow self-isolation guidance. If a returning traveler is tested and is negative, they should resume self-isolation for the remainder of their 14-day isolation period in case their symptoms worsen and require reassessment/re-testing.

**Contact tracing for airplane passengers**

As travel restrictions ease over time, the most timely way to share information about potential exposures on conveyances is through public posting of flight/conveyance information, and notification to the airline for informing crew members. This applies to both international and domestic flights.

PHUs should send the following information to PHO ([EPIR@oahpp.ca](mailto:EPIR@oahpp.ca)) if they identify a flight/cruise with a confirmed case:

- Airline, flight number, date, departure location, arrival location, relevant rows
- Cruise line, dates of travel, departure port, arrival port
- Symptom onset date, or positive specimen date if case is asymptomatic

In addition to information for public posting of flight/conveyance information, PHUs may be required to provide further information regarding international travel for PHAC to process the International Jurisdiction Notification, e.g., whether or not the case is a Canadian national; detailed travel information while abroad (i.e., accommodation information, potential exposures).
Tools

PHUs may use the following tools to conduct case and contact management activities. Additional resources and appendices may be added to support case and contact management activities, and updated documents can be found on the Ministry of Health website.

- **Appendix 1: Ontario’s Severe Acute Respiratory Infection (SARI) Case Report Form** – PHUs may use this form to help guide their case interview and collection of information from probable and confirmed cases or their proxies. PHUs must enter all cases in iPHIS or other appropriate database.

- **Appendix 2: Routine Activities Prompt Worksheet for Cases** – PHUs may use this sample worksheet (or a similar tool) to identify potential exposures that may have led to disease acquisition in a case. Along with the SARI Case Report Form in Appendix 1, this worksheet can also be used to interview the case or their proxy to collect detailed information and to investigate potential exposures in the 14 days before onset of symptoms.

- **Appendix 3: Daily Clinical Update Form for a Case Managed in an Acute Care Setting and Appendix 4: Daily Clinical Update Form for a Case Managed in a Household Setting** – PHUs may use these sample forms (or a similar tool) to monitor the health status of a probable or confirmed case until they are cleared.

- **Appendix 5: Close Contact Tracing Worksheet** – PHUs may use this sample worksheet (or a similar tool) to identify close contacts of a probable or confirmed case.

- **Appendix 6: Daily Contact Clinical Update Form** – PHUs may use this sample form (or a similar tool) to follow-up and monitor contacts with high-risk exposures.

- **Appendix 7: Self-Isolation for COVID-19 Cases or Other Individuals in the Household** - This guidance can be used to support individuals undergoing testing (with symptoms or known contact to a confirmed or probable case), anyone being asked to self-isolate, and others in the household of a case.
Additional Resources

- Public Health Ontario Public Resources
- Public Health Agency of Canada's Public Health Management of Cases and Contacts for COVID-19
- Public Health Agency of Canada's IPAC for COVID-19: Interim Guidance for Home Care Settings
- Public Health Agency of Canada's COVID-19: For Health Professionals website
- Centers for Disease Control and Prevention's COVID-19 website
- European Centre for Disease Prevention and Control’s COVID-19 website
- Ministry of Health’s COVID-19 website
- Provincial Infectious Diseases Advisory Committee’s Tools for Preparedness: Triage, Screening and Patient Management of Middle East Respiratory Syndrome Coronavirus (MERS-CoV) Infections in Acute Care Settings
- Government of Canada’s COVID-19 Affected Areas list
- World Health Organization’s Disease Outbreak News website, and COVID-19 website
## Document History

<table>
<thead>
<tr>
<th>Revision Date</th>
<th>Document Section</th>
<th>Description of Revisions</th>
</tr>
</thead>
<tbody>
<tr>
<td>January 30 2020</td>
<td></td>
<td>Document was created.</td>
</tr>
<tr>
<td>February 5 2020</td>
<td>Contact Management – Public Health Advice</td>
<td>Language included to reflect policy change: self-isolation of 14 days for those returning from Hubei province and for close contacts of cases.</td>
</tr>
<tr>
<td>February 7, 2020</td>
<td>Throughout Document</td>
<td>Updates to reflect changes to case definition and self-isolation</td>
</tr>
<tr>
<td>February 12 2020</td>
<td>Case and Contact Management</td>
<td>Updates to language around risk level and corresponding level of self isolation/ self monitoring</td>
</tr>
<tr>
<td></td>
<td>Travelers from Affected Areas</td>
<td>Addition of Table 3</td>
</tr>
<tr>
<td>March 3 2020</td>
<td>Updates throughout document</td>
<td>Updates based on new case definition and evolving advice based on travel history of patient</td>
</tr>
<tr>
<td>March 25 2020</td>
<td>Updates throughout document</td>
<td>Change in Purpose section; guidance on testing, explanation on case definition, assessment and management of persons suspected of COVID-19, Information on pets</td>
</tr>
<tr>
<td>April 15 2020</td>
<td>Updates throughout document</td>
<td>Updates on case definition description, travelers from outside of Canada, link to other guidance (e.g. provincial testing), updates to streamline language throughout</td>
</tr>
<tr>
<td>June 23 2020</td>
<td>Updates throughout document</td>
<td>Major updates to most sections, addition of several reference tables, moved to 2 risk exposure levels: low and high risk, moved appendices to become separate documents.</td>
</tr>
</tbody>
</table>